Are you excited for a new year with the NLA? While we still have so much to accomplish in 2022, there is a lot of excitement about what we will be doing as we head into 2023. The NLA has developed a series of educational activities and engagement opportunities for our members and those interested in lipid management near and far, and we cannot wait for you to take advantage of all the offerings! Here are some of the plans for 2023:
News Stories
Jacksonville, Florida - (August 25, 2022) - The American College of Cardiology (ACC) announced the release of the 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. The new Expert Consensus Decision Pathway provides practical guidance for lowering LDL-C with nonstatin therapies.
Name: Top Stories
Regeneron Pharmaceuticals, Inc. announced positive results from a Phase 3 trial evaluating Evkeeza® (evinacumab) in children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). The trial met its primary endpoint, showing children who added investigational evinacumab to other lipid-lowering therapies reduced their low-density lipoprotein-cholesterol (LDL-C) by an average of 48% at week 24 of the study. Anne C.
Name: NLA News